智翔金泰: 自愿披露关于GR1802注射液启动过敏性鼻炎适应症III期临床试验的公告

Group 1 - The company, Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd., has announced the initiation of a Phase III clinical trial for GR1802 injection, targeting allergic rhinitis [1][2] - GR1802 injection is a recombinant fully human anti-IL-4Rα monoclonal antibody, designed to specifically bind to the IL-4Rα on cell surfaces, blocking the binding of IL-4 and IL-13, thereby inhibiting Th2-mediated inflammatory responses [1][2] - The drug has already received clinical trial approval for multiple indications, including moderate to severe atopic dermatitis, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria, with asthma currently in Phase II and pediatric atopic dermatitis in Phase Ib/II trials [2] Group 2 - As of the announcement date, only two other drugs targeting the same receptor have been approved for marketing in China [2] - The company emphasizes the importance of adhering to regulatory requirements for drug registration and the lengthy, complex process of drug development, which is subject to various uncertainties [2]